Major TB reduction impossible without expansion of ART coverage

Keith Alcorn
Published: 08 July 2019

Tuberculosis incidence in sub-Saharan Africa is falling too slowly to meet global targets of an 80% reduction by 2030, and where incidence is falling, the decline is strongly associated with the extent of antiretroviral coverage in people living with HIV, a study by former World Health Organization modelling experts has found.

The findings, published in the Bulletin of the World Health Organization in June 2019, come from a modelling study carried out by Christopher Dye and Brian Williams.

They looked at the relationship between TB incidence, diagnosis, treatment, HIV burden and antiretroviral coverage in 12 countries in sub-Saharan Africa with a high standard of TB and HIV surveillance data.

TB disproportionately affects people living with HIV, with immune suppression leading to the reactivation of latent TB infection. Countries with the highest prevalence of HIV also have amongst the highest TB incidence. Antiretroviral therapy reduces the risk of developing TB, as does isoniazid preventive therapy.

With little evidence that TB diagnosis and treatment are leading to an acceleration in TB reduction, increasing the coverage of ART is important.

Review of national surveillance data showed that TB incidence fell in all countries in the region between 2003 and 2016 in HIV-positive people and in all countries except Uganda in HIV-negative people. The average annual reduction in incidence in people with HIV ranged from 8.1% a year in Botswana, 8.7% in Zimbabwe and 9% in Namibia to only 0.5% in South Africa. Incidence per 100,000 people with HIV was highest in Lesotho (979 per 100,000) and lowest in Uganda (146 per 100,000) and Rwanda (46 per 100,000).

The burden of HIV among newly-diagnosed TB patients varied considerably; whereas 47% of newly-diagnosed TB patients tested HIV-positive in Tanzania, 70% in Botswana and Zambia, 78% in Zimbabwe and 84% in eSwatini (Swaziland) did so.

The researchers modelled the impact of antiretroviral treatment and isoniazid preventive therapy on TB incidence using data on availability and uptake of both interventions. Both interventions have been shown to reduce the incidence of TB in people with HIV They also looked at the impact of TB case detection and TB treatment on TB incidence, assuming that detection and treatment of TB would interrupt transmission chains and prevent new cases.

TB incidence and prevalence rose in all countries from 1990 as a consequence of the rise in HIV prevalence but began to decline as case detection and treatment outcomes improved.

Antiretroviral therapy began to be introduced from 2003, although the rate of increase in coverage varied between countries. Whereas coverage increased at a steady rate between 2003 and 2016 in Botswana, coverage began to increase at a more rapid pace after 2008 in South Africa, eSwatini, Namibia, and Zimbabwe.

Overall, modelling found an inverse correlation between ART coverage and TB incidence, and regression analysis found that ART coverage was associated with a higher proportion of TB cases prevented in people living with HIV (r2=0.68, p< 0.001).

Although approximately 500,000 TB cases were prevented in South Africa between 2003 and 2016 due to antiretroviral treatment, the model estimates, this only amounted to preventing 11.2% of TB cases, because of limited ART coverage.

In the 12 countries studied, antiretroviral treatment prevented between 1.88 million and 2.06 million TB cases in people living with HIV, or 17.6% of the cases that would have occurred otherwise.

In contrast, isoniazid preventive therapy had a negligible effect on TB incidence despite strong evidence of effectiveness and guidance from the World Health Organization on the need to implement IPT. Isoniazid preventive therapy coverage did not exceed 4.2% in South Africa, the country most successful in implementing IPT, and three countries in the region (South Africa, Malawi and Zimbabwe) accounted for 91% of all IPT coverage.

The researchers failed to find any correlation between the estimated level of case detection and TB incidence across the 12 countries. If case detection is higher, more TB cases should be diagnosed and treated, preventing onward transmission.

In conclusion, the authors say that TB incidence is declining too slowly to meet international targets. To meet the 2030 WHO End TB strategy’s target of an 80% reduction in TB incidence, the incidence of TB needs to fall by 10% a year. With little evidence that TB diagnosis and treatment are leading to an acceleration in TB reduction, increasing the coverage of ART will make an important contribution to reducing TB incidence where the prevalence of HIV is high.


Dye C, Williams B. Tuberculosis decline in populations affected by HIV: a retrospective study of 12 countries in WHO African Region. Bull World Health Organ 97: 405-414, 2019.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.